239 related articles for article (PubMed ID: 20946740)
1. Network support as a prognostic indicator of drinking outcomes: the COMBINE Study.
Longabaugh R; Wirtz PW; Zywiak WH; O'Malley SS
J Stud Alcohol Drugs; 2010 Nov; 71(6):837-46. PubMed ID: 20946740
[TBL] [Abstract][Full Text] [Related]
2. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol; 2012 Mar; 46(2):121-31. PubMed ID: 21925828
[TBL] [Abstract][Full Text] [Related]
3. Relationship between medication adherence and treatment outcomes: the COMBINE study.
Zweben A; Pettinati HM; Weiss RD; Youngblood M; Cox CE; Mattson ME; Gorroochurn P; Ciraulo D
Alcohol Clin Exp Res; 2008 Sep; 32(9):1661-9. PubMed ID: 18616687
[TBL] [Abstract][Full Text] [Related]
4. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
[TBL] [Abstract][Full Text] [Related]
5. The effects of drinking goal on treatment outcome for alcoholism.
Bujarski S; O'Malley SS; Lunny K; Ray LA
J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
[TBL] [Abstract][Full Text] [Related]
6. Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
Falk D; Wang XQ; Liu L; Fertig J; Mattson M; Ryan M; Johnson B; Stout R; Litten RZ
Alcohol Clin Exp Res; 2010 Dec; 34(12):2022-34. PubMed ID: 20659066
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.
Greenfield SF; Pettinati HM; O'Malley S; Randall PK; Randall CL
Alcohol Clin Exp Res; 2010 Oct; 34(10):1803-12. PubMed ID: 20645934
[TBL] [Abstract][Full Text] [Related]
8. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
9. Does family history of alcoholism moderate naltrexone's effects on alcohol use?
Capone C; Kahler CW; Swift RM; O'Malley SS
J Stud Alcohol Drugs; 2011 Jan; 72(1):135-40. PubMed ID: 21138720
[TBL] [Abstract][Full Text] [Related]
10. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment alcohol drinking goals are associated with treatment outcomes.
Dunn KE; Strain EC
Alcohol Clin Exp Res; 2013 Oct; 37(10):1745-52. PubMed ID: 23800222
[TBL] [Abstract][Full Text] [Related]
12. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.
Weiss RD; O'malley SS; Hosking JD; Locastro JS; Swift R;
J Stud Alcohol Drugs; 2008 Nov; 69(6):878-84. PubMed ID: 18925346
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Drug Alcohol Depend; 2010 Mar; 107(2-3):221-9. PubMed ID: 19969427
[TBL] [Abstract][Full Text] [Related]
15. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
16. Reward and relief dimensions of temptation to drink: construct validity and role in predicting differential benefit from acamprosate and naltrexone.
Roos CR; Mann K; Witkiewitz K
Addict Biol; 2017 Nov; 22(6):1528-1539. PubMed ID: 27480445
[TBL] [Abstract][Full Text] [Related]
17. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study.
Ray LA; Oslin DW
Drug Alcohol Depend; 2009 Dec; 105(3):256-8. PubMed ID: 19717248
[TBL] [Abstract][Full Text] [Related]
19. Blood glucose level, alcohol heavy drinking, and alcohol craving during treatment for alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study.
Leggio L; Ray LA; Kenna GA; Swift RM
Alcohol Clin Exp Res; 2009 Sep; 33(9):1539-44. PubMed ID: 19485973
[TBL] [Abstract][Full Text] [Related]
20. Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials.
Witkiewitz K; Pearson MR; Hallgren KA; Maisto SA; Roos CR; Kirouac M; Wilson AD; Montes KS; Heather N
Addiction; 2017 Dec; 112(12):2112-2121. PubMed ID: 28511286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
